{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+Activated+Factor+VII+%28rFVIIa%29",
    "query": {
      "intervention": "Recombinant Activated Factor VII (rFVIIa)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 48,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Recombinant+Activated+Factor+VII+%28rFVIIa%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T10:09:48.924Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00443573",
      "title": "Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colon Cancer"
      ],
      "interventions": [
        {
          "name": "recombinant nematode anticoagulant protein c2 (rNAPc2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ARCA Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 100,
      "start_date": "2006-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-05-07",
      "last_synced_at": "2026-10-06T10:09:48.924Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00443573"
    },
    {
      "nct_id": "NCT01561937",
      "title": "Use of Activated Recombinant Human Factor VII to Reduce Bleeding Caused by Warfarin Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Haemostasis",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "warfarin",
          "type": "DRUG"
        },
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 127,
      "start_date": "2007-01",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2016-11-25",
      "last_synced_at": "2026-10-06T10:09:48.924Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01561937"
    },
    {
      "nct_id": "NCT00116012",
      "title": "Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronary Disease"
      ],
      "interventions": [
        {
          "name": "rNAPc2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ARCA Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 300,
      "start_date": "2005-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2006-11-29",
      "last_synced_at": "2026-10-06T10:09:48.924Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00116012"
    },
    {
      "nct_id": "NCT00486278",
      "title": "Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia A",
        "Haemophilia B"
      ],
      "interventions": [
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        },
        {
          "name": "vatreptacog alfa (activated)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "12 Years and older · Male only"
      },
      "enrollment_count": 51,
      "start_date": "2007-06",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-10-06T10:09:48.924Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00486278"
    },
    {
      "nct_id": "NCT01757405",
      "title": "Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A",
        "Hemophilia B"
      ],
      "interventions": [
        {
          "name": "Recombinant Factor VIIa BI (rFVIIa BI)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "MALE",
        "summary": "12 Years to 65 Years · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2013-02-20",
      "completion_date": "2014-11-11",
      "has_results": true,
      "last_update_posted_date": "2021-05-11",
      "last_synced_at": "2026-10-06T10:09:48.924Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01757405"
    },
    {
      "nct_id": "NCT01439971",
      "title": "Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "PF-05280602",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Catalyst Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "MALE",
        "summary": "18 Years to 64 Years · Male only"
      },
      "enrollment_count": 29,
      "start_date": "2011-12",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2017-05-12",
      "last_synced_at": "2026-10-06T10:09:48.924Z",
      "location_count": 9,
      "location_summary": "San Diego, California • New Haven, Connecticut • Chicago, Illinois + 3 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01439971"
    },
    {
      "nct_id": "NCT02020369",
      "title": "Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hemophilia A With Inhibitors",
        "Hemophilia B With Inhibitors"
      ],
      "interventions": [
        {
          "name": "Coagulation Factor VIIa (Recombinant)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "rEVO Biologics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "MALE",
        "summary": "12 Years to 75 Years · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2014-04",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-10-06T10:09:48.924Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02020369"
    },
    {
      "nct_id": "NCT00108758",
      "title": "Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Bleeding Disorder",
        "Haemophilia A With Inhibitors",
        "Haemophilia B With Inhibitors"
      ],
      "interventions": [
        {
          "name": "activated recombinant human factor VII",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "2 Years and older · Male only"
      },
      "enrollment_count": 23,
      "start_date": "2004-03",
      "completion_date": "2005-11",
      "has_results": false,
      "last_update_posted_date": "2017-01-12",
      "last_synced_at": "2026-10-06T10:09:48.924Z",
      "location_count": 13,
      "location_summary": "Berkeley, California • Los Angeles, California • Chicago, Illinois + 9 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00108758"
    },
    {
      "nct_id": "NCT00184548",
      "title": "Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acquired Bleeding Disorder",
        "Trauma"
      ],
      "interventions": [
        {
          "name": "eptacog alfa (activated)",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 554,
      "start_date": "2005-10",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2014-06-25",
      "last_synced_at": "2026-10-06T10:09:48.924Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00184548"
    },
    {
      "nct_id": "NCT00243243",
      "title": "Effect of rFVIIa on Peri-operative Blood Loss in Patients Undergoing Major Burn",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Burns"
      ],
      "interventions": [
        {
          "name": "Recombinant Factor VIIa",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "United States Army Institute of Surgical Research",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2006-01",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2016-05-26",
      "last_synced_at": "2026-10-06T10:09:48.924Z",
      "location_count": 1,
      "location_summary": "Fort Sam Houston, Texas",
      "locations": [
        {
          "city": "Fort Sam Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00243243"
    }
  ]
}